Celebrating the Path-Breaking Research That Lead to Coronavirus Vaccines

The Washington Post tells the remarkable story of how both Moderna's vaccine and the Pfizer/BioNTech vaccine relied on a specially designed spike protein partially created by America's Vaccine Research Center — along with messenger RNA, "a technology never before harnessed in an approved vaccine." And also decades of path-breaking research: If, as expected in the next few weeks, regulators give those vaccines the green light, the technology and the precision approach to vaccine design could turn out to be the pandemic's silver linings: scientific breakthroughs that could begin to change the trajectory of the virus this winter and also pave the way for highly effective vaccines and treatments for other diseases. Vaccine development typically takes years, even decades. The progress of the last 11 months shifts the paradigm for what's possible, creating a new model for vaccine development and a toolset for a world that will have to fight more never-before-seen viruses in years to come. But the pandemic wasn't a sudden eureka moment — it was a catalyst that helped ignite lines of research that had been moving forward for years, far outside the spotlight of a global crisis... Long before the pandemic, [Vaccine Research Center deputy director Barney] Graham worked with colleagues there and in academia to create a particularly accurate 3-D version of the spiky proteins that protrude from the surface of coronaviruses — an innovation that was rejected for publication by scientific journals five times because reviewers questioned its relevance. His laboratory partnered with one of the companies, Moderna, working to develop a fast and flexible vaccine technology, in the hope that science would be ready to respond when a pandemic appeared. "People hear about [vaccine progress] and think someone just thought about it that night. The amount of work — it's really a beautiful story of fundamental basic research,", said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases [of which the center is an intramural division]... The leading coronavirus vaccine candidates in the United States began their development not in January when a mysterious pneumonia emerged in Wuhan, China, but decades ago — with starts and stops along the way.... Unlike fields that were sparked by a single powerful insight, [Ugur Sahin, chief executive of BioNTech] said that the recent success of messenger RNA vaccines is a story of countless improvements that turned an alluring biological idea into a beneficial technology. "This is a field which benefited from hundreds of inventions," said Sahin, who noted that when he started BioNTech in 2008, he cautioned investors that the technology would not yield a product for at least a decade. He kept his word: Until the coronavirus sped things along, BioNTech projected the launch of its first commercial project in 2023... On Jan. 13, Moderna RNA scientist Melissa Moore came into work and found her team already busy translating the stabilized spike protein into their platform. The company could start making the vaccine almost right away because of its experience manufacturing experimental cancer vaccines, which involves taking tumor samples and developing personalized vaccines in 45 days. The Post tries to convey how meaningful this moment is for the scientists involved. Years ago one BioNTech scientist had told their spouse, "I just want to live long enough that I can help the RNA go to the patient. I want to see...at least one person would be helped with this treatment." And when the Vaccine Research Center's deputy director finally learned how effective the Pfizer/BioNTech vaccine was, "I just let it all go. "I was sobbing, I guess, is the term."

Read more of this story at Slashdot.

from Slashdot https://ift.tt/3qtZBHL

Share on FacebookPlus on Google+

SUBSCRIBE TO OUR NEWSLETTER